CN Patent

CN116098887A — 用于治疗史密斯-马吉利综合征的他司美琼

Assigned to Vanda Pharmaceuticals Inc · Expires 2023-05-12 · 3y expired

What this patent protects

本发明涉及用于治疗史密斯‑马吉利综合征的他司美琼。本发明的实施方式涉及患有史密斯‑马吉利综合征(SMS)的个体中的睡眠障碍的治疗。具体而言，涉及他司美琼在制备用于治疗患有SMS的患者的睡眠失调的药物中的应用，其中，所述治疗包括每日一次向所述患者内部施用有效量的他司美琼以减少光诱导的褪黑激素产生。

USPTO Abstract

本发明涉及用于治疗史密斯‑马吉利综合征的他司美琼。本发明的实施方式涉及患有史密斯‑马吉利综合征(SMS)的个体中的睡眠障碍的治疗。具体而言，涉及他司美琼在制备用于治疗患有SMS的患者的睡眠失调的药物中的应用，其中，所述治疗包括每日一次向所述患者内部施用有效量的他司美琼以减少光诱导的褪黑激素产生。

Drugs covered by this patent

Patent Metadata

Patent number: CN116098887A
Jurisdiction: CN
Classification: —
Expires: 2023-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.